| Description | Azvudine (FNC) is a potent nucleoside reverse transcriptase inhibitor (NRTI), with antiviral activity on HIV, HBV and HCV. Azvudine inhibits NRTI-resistant viral strains. Azvudine exerts highly potent inhibition on HIV-1 (EC50s ranging from 0.03 to 6.92 nM) and HIV-2 (EC50s ranging from 0.018 to 0.025 nM). |
| In vitro | Azvudine 对NRTIs抗性菌株HIV-174V、PIs抗性菌株HIV-1L10R/M46I/L63P/V82T/I84V和HIV-1RF V82F/184V，以及FIs抗性菌株pNL4-3 gp41 (36G) V38A/N42T表现出敏感性，其对这些抗性菌株的EC50值分别为0.11, 0.14, 0.37和0.36 nM。 Azvudine对野生型HIV-1IIIB和HIV-1RF显示出强烈的抑制作用，其EC50值范围为30到110 pM。针对HIV-1KM018、HIV-1TC-1和HIV-1WAN T69N的EC50值分别为6.92, 0.34和0.45 nM[1]。 |
| Target activity | HIV-1:0.03 to 6.92 Nm(EC50), HIV-2:0.025 nM(EC50) |
| Synonyms | 4-氨基-1-(4-C-叠氮基-2-脱氧-2-氟-BETA-D-呋喃阿拉伯糖基)-2(1H)-嘧啶酮, FNC, RO-0622 |
| molecular weight | 286.22 |
| Molecular formula | C9H11FN6O4 |
| CAS | 1011529-10-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 5.2 mg/ml (18.17 mM) H2O: 50 mg/mL |
| References | 1. Wang RR, et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One. 2014 Aug 21;9(8):e105617. |